These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 425062)

  • 41. [Treatment of haemorrhages in a haemophiliac with factor-VIII inhibitor (author's transl)].
    Angelkort B; Stürner KH
    Dtsch Med Wochenschr; 1979 Feb; 104(5):182-6. PubMed ID: 759178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor].
    Scharf R; Kucharski W; Lopaciuk S; Celińska W; Dmytrow A; Domański K; Gonet S; Miastkowski Z; Nowakowska I; Przybylski A
    Acta Haematol Pol; 1991; 22(1):92-9. PubMed ID: 1823972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blood products used in the treatment of hemophilia.
    Krasnoff AR; Mangione RA
    Hosp Pharm; 1982 Nov; 17(11):598-9, 602-4. PubMed ID: 10318549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-factor VIII anamnesis after factor IX complex.
    Palascak JE; Shapiro SR
    N Engl J Med; 1977 Dec; 297(25):1403. PubMed ID: 927458
    [No Abstract]   [Full Text] [Related]  

  • 45. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
    Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM
    Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune response induced by porcine factor VIII in severe hemophiliacs with antibody to F VIII.
    Verroust F; Allain JP
    Thromb Haemost; 1982 Oct; 48(2):238. PubMed ID: 6817447
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of inhibitor patients with activated prothrombin complex concentrates.
    Penner JA
    Prog Clin Biol Res; 1984; 150():291-308. PubMed ID: 6431434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of non-activated prothrombin concentrate in the management of haemophilia A with factor VIII antibodies.
    Price DA; d'Souza S; Ekert H
    Aust N Z J Med; 1977 Jun; 7(3):286-90. PubMed ID: 269689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FEIBA: mode of action.
    Turecek PL; Váradi K; Gritsch H; Schwarz HP
    Haemophilia; 2004 Sep; 10 Suppl 2():3-9. PubMed ID: 15385040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of immune responses following 102 infusions of autoplex in 18 hemophilic patients with antibody to factor VIII.
    Laurian Y; Girma JP; Lambert T; Meyer D; Larrieu MJ
    Blood; 1984 Feb; 63(2):457-62. PubMed ID: 6419798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates.
    Kelly P; Penner JA
    JAMA; 1976 Nov; 236(18):2061-4. PubMed ID: 989788
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.
    Stenbjerg S; Jørgensen J
    Acta Med Scand; 1978; 203(6):471-6. PubMed ID: 665313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factor Xa and prothrombin: mechanism of action of FEIBA.
    Turecek PL; Varadi K; Gritsch H; Auer W; Pichler L; Eder G; Schwarz HP
    Vox Sang; 1999; 77 Suppl 1():72-9. PubMed ID: 10529694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
    Parry DH; Bloom AL
    J Clin Pathol; 1978 Nov; 31(11):1102-5. PubMed ID: 739057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasmapheresis: its value in the management of patients with antibodies to factor VIII.
    Francesconi M; Korninger C; Thaler E; Niessner H; Höcker P; Lechner K
    Haemostasis; 1982; 11(2):79-86. PubMed ID: 6806156
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term high dose factor VIII treatment of 3 haemophiliacs with factor VIII inhibitor.
    Scheibel E; Feddersen C; Hertz H
    Scand J Haematol; 1985 May; 34(5):378-84. PubMed ID: 3925544
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance to activated F IX concentrate (FEIBA).
    Stenbjerg S; Jorgensen J
    Scand J Haematol; 1977 May; 18(5):421-6. PubMed ID: 877518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII.
    Kernoff PB; Thomas ND; Lilley PA; Matthews KB; Goldman E; Tuddenham EG
    Blood; 1984 Jan; 63(1):31-41. PubMed ID: 6418234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody.
    Blatt PM; White GC; McMillan CW; Webster WP
    JAMA; 1984 Jan; 251(1):67. PubMed ID: 6418898
    [No Abstract]   [Full Text] [Related]  

  • 60. Use of prothrombin complex concentrates in the treatment of a hemophilic patient with an inhibitor of factor VIII.
    Sonoda T; Solomon A; Krauss S; Cruz P; Jones FS; Levin J
    Blood; 1976 Jun; 47(6):983-9. PubMed ID: 1276480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.